Entity

Time filter

Source Type

Thorold, Canada

Thapa S.P.,Kangwon National University | Park D.H.,Kangwon National University | Kim W.S.,Norgen Biotek Corporation | Choi B.S.,Seoul National University | And 4 more authors.
Genome | Year: 2013

Japanese Erwinia pyrifoliae strains cause bacterial shoot blight of pear (BSBP) in Japan. The genetics of Japanese Erwinia remains largely unknown relative to the abundant genomic information available for other Erwinia strains. We compared the genome of Japanese and Korean E. pyrifoliae strains along with those of E. amylovora and E. tasmaniensis. Comparisons with the Korean E. pyrifoliae strain revealed numerous gene insertions/deletions, rearrangements, and inversions in the central regions of the chromosomes. Approximately 80% (2843) of coding DNA sequences (CDSs) are shared by these two genomes which represent about three-quarters of the genome, and there are about 20% unique CDSs. Comparative analysis with closely related erwinias showed that 1942 (more than 50%) core open reading frames (ORF) are shared by all these strains. In addition to two type III secretion systems (hrp/dsp and inv/spa), the genome of Ejp617 encodes numerous virulence factors, including a type VI secretion system, an exopolysaccharide synthesis cluster, and another protein secretion system present in plant pathogenic Erwinia strains. The availability of whole genome sequence should provide a resource to further improve the understanding of pathogenesis in Japanese E. pyrifoliae Ejp617 and to facilitate evolutionary studies among the species of the genus Erwinia. © 2013 Published by NRC Research Press. Source


Disclosed are microRNA biomarkers and use thereof for screening and diagnosis of prostate cancer and benign prostatic hyperplasia. This invention provides a method for screening for prostate cancer in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for prostate cancer; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the over-expression of miR-1825 or under the expression of miR-484 is indicative of prostate cancer. In another aspect, provided is a method for screening for benign prostatic hyperplasia in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for benign prostatic hyperplasia; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the under expression of miR-498 is indicative of benign prostatic hyperplasia.


Patent
Norgen Biotek Corporation | Date: 2011-07-22

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for seating the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in murine sample.


Patent
Norgen Biotek Corporation | Date: 2014-04-30

The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in a collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for sealing the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in a urine sample.


Provided is a nucleic acid preservative comprising at least one reducing agent, at least one chaotropic substance, at least one polyamine substance and at least one chelating agent and uses thereof, and a method for the preservation of nucleic acids in a biological sample. Further provided are kits for use in the preservation of nucleic acids in a biological sample, and more particularly, a blood sample.

Discover hidden collaborations